VaccinesCOVID vaccines and cancer — what do critics say?
- Jerzy Zięba — „Kowidowa” prawda
- Prof. Sucharit Bhakdi — mRNA Vaccine Toxicity — M. Palmer i S. Bhakdi i in. (2023)
- COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms. · Oncotarget 2026
- COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective. · Med Sci (Basel) 2026
- Interpreting vaccine-associated survival differences in immune checkpoint inhibitor therapy. · Proc Natl Acad Sci U S A 2026
- Orthomolecular Medicine News Service — A Hallmark of Covid-19: Cytokine Storm/Oxidative Stress and its Integrative Mechanism
- Orthomolecular Medicine News Service — Heart Failure or Therapy Failure? Toxins Cause Cardiomyopathy
Jerzy Zięba points out that the effect of the vaccine on the possibility of cancer developing remains unknown.
- Prof. Sucharit Bhakdi cites pathologists’ observations of an increase in the number and malignancy of cancers since COVID-19 vaccinations began, as well as recurrences of diseases previously considered cured.
- Bhakdi interprets these observations as a sign of significant weakening of the immune system after vaccination and considers frequent booster doses a possible threat to public health.
What the authors write
The vaccine leaflet states that its effect on the possibility of cancer developing remains unknown.
Prof. Sucharit Bhakdi cites pathologists’ observations of an increase in the number and malignancy of cancers since COVID-19 vaccinations began, as well as recurrences of diseases previously considered cured.
Prof. Sucharit Bhakdi interprets these observations as pointing to significant weakening of the immune system after vaccination.
Prof. Sucharit Bhakdi considers frequent booster doses a possible threat to public health.
Research from PubMed · Europe PMC
We selected 3 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 4 798.
The review collected reports of cancers appearing after vaccination or infection, but most of the data came from case reports and do not prove a causal link.
Aim of the study: A growing number of peer-reviewed publications have reported diverse cancer types appearing in temporal association with COVID-19 vaccination or infection. To characterize the nature and scope of these reports, a systematic literature search from January 2020 to October 2025 was conducted based on specified eligibility criteria.
Results: Most of the studies documented hematologic malignancies (non-Hodgkin's lymphomas, cutaneous lymphomas, leukemias), solid tumors (breast, lung, melanoma, sarcoma, pancreatic cancer, and glioblastoma), and virus-associated cancers (Kaposi and Merkel cell carcinoma). Across reports, several recurrent themes emerged: (1) unusually rapid progression, recurrence, or reactivation of preexisting indolent or controlled disease, (2) atypical or localized histopathologic findings, including involvement of vaccine injection sites or regional lymph nodes, and (3) proposed immunologic links between acute infection or vaccination and tumor dormancy, immune escape, or microenvironmental shifts. The predominance of case-level observations and early population-level data demonstrates an early phase of potential safety-signal detection.
“Not stated” does not mean nobody paid — the database does not always record it.
The review describes observational associations between mRNA vaccination and better survival during immunotherapy, but notes that some of the effect may be due to selection bias.
Aim of the study: Since 2020, billions of doses of COVID-19 messenger RNA (mRNA) lipid nanoparticle vaccines have been administered worldwide, generating one of the largest pharmacovigilance databases for a modern therapeutic class.
Results: Here, we examine the mechanistic basis and available evidence for the repurposing of licensed COVID-19 mRNA vaccines as antigen-agnostic immunomodulators. We identified five candidate contexts for prospective evaluation-namely, (1) PD-L1-negative non-small cell lung cancer initiating ICI therapy, (2) perioperative immune dysfunction in major cardiac surgery, (3) chronic hepatitis B, (4) chronic HIV with persistent immune exhaustion, and (5) sepsis-induced immunoparalysis. Methodological foundations for confirmatory assessment-comprising target trial emulation, Mendelian randomization, and pragmatic trial design-are now sufficiently developed to enable implementation. Prospective evaluation of the antigen-agnostic repurposing hypothesis is operationally feasible, albeit constrained by residual confounding and uncertainty about the durability of vaccine-induced innate reprogramming.
“Not stated” does not mean nobody paid — the database does not always record it.
Among patients treated with immune checkpoint inhibitors, vaccination was associated with lower mortality, but the results did not point to a specific effect of mRNA vaccines.
Aim of the study: Recent studies proposed that SARS-CoV-2 mRNA vaccination may sensitize tumors to immune checkpoint inhibitor (ICI) therapy through immune modulation. Using 100% national Medicare fee-for-service claims data, we evaluated whether survival differences among vaccinated patients receiving ICIs were specific to mRNA vaccines.
Results: Using 100% national Medicare fee-for-service claims data, we evaluated whether survival differences among vaccinated patients receiving ICIs were specific to mRNA vaccines. Among 121,676 beneficiaries initiating systemic anticancer therapy, including 10,824 initiating ICIs, vaccination near treatment initiation was associated with lower mortality across mRNA COVID-19, adenoviral COVID-19, and influenza vaccines. We found that survival associations and formal vaccine-ICI interaction effects were similar across vaccine platforms. These findings suggest that currently available population-level survival data do not isolate an mRNA-specific tumor-sensitization mechanism.
“Not stated” does not mean nobody paid — the database does not always record it.
Perspectives and opinion materials
The content below presents the authors’ opinions, interpretations and hypotheses. It is not treated as equal to scientific studies and systematic reviews.
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.